Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16081352 | 0.80 | SMN1; SMN2 (0.33) | HTT | |
| SCHEMBL16850576 | 0.78 | ALDH1A1 (0.35) | ALDH1A1LMNAHSD17B10HTTALOX15 | |
| SCHEMBL19545305 | 0.78 | HTT (0.31) | HTT | |
| SCHEMBL6762809 | 0.77 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10HTTALOX15 | |
| SCHEMBL16077769 | 0.70 | CPT2 (0.32) | LMNATSHR | |
| SCHEMBL4093235 | 0.70 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10HTTALOX15 | |
| SCHEMBL28230301 | 0.70 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL1164307 | 0.70 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10HTTALOX15 | |
| SCHEMBL7787921 | 0.69 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10HTTALOX15 | |
| SCHEMBL8074523 | 0.69 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10HTTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116670140-A | Macrocyclic compounds containing 1,3, 4-oxadiazole rings as modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4192829-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-116171154-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20220041621-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2022-02-10 | — | — | US | disclosed |
| WO-2022032068-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-02-10 | — | — | WO | disclosed |
| EP-3825312-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Pharmasset LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| CN-104829688-B | Macrocyclic proline derived HCV serine protease inhibitors | 益安药业 | 2021-02-09 | — | — | CN | disclosed |
| US-20200270303-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2020-08-27 | — | — | US | disclosed |
| US-10442792-B2 | Synthetic route to anti-viral agents | ABBVIE INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190263860-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2014-09-18 | — | — | US | disclosed |
| WO-2014145095-A1 | MACROCYCLIC AND BICYCLIC INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140194350-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194350-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2014-01-16 | — | — | US | disclosed |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2014-01-16 | — | — | US | disclosed |
| WO-2014008285-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263860-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | ALDH1A1 1434/4885LMNA 3069/4885HSD17B10 1161/4885 |
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | PREP, PRSS1, PEPD | ALDH1A1 1434/4885LMNA 3069/4885HSD17B10 1161/4885 |
| US-20200270303-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | ALDH1A1 1434/4885LMNA 3069/4885HSD17B10 1161/4885 |
| US-10442792-B2 | Synthetic route to anti-viral agents | ACE, ACE2, PREP | ALDH1A1 4400/4885LMNA 3391/4885HSD17B10 3238/4885 |
| US-20220041621-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | ALDH1A1 3972/4885LMNA 4099/4885HSD17B10 2742/4885 |
| US-20140194350-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | ALDH1A1 1434/4885LMNA 3069/4885HSD17B10 1161/4885 |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, LIPC | ALDH1A1 200/4885LMNA 2072/4885HSD17B10 220/4885 |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | ALDH1A1 112/4885LMNA 2502/4885HSD17B10 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.